Mariano Galdiero

Mariano Galdiero

Auto-generated profile, based on publicly available information

Mariano Galdiero

“Federico II” University of Naples

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
Annamaria ColaoAnnamaria Colao
Annamaria Colao
RARenata S. Auriemma
Renata S. Auriemma
MGMariano Galdiero
Mariano Galdiero
GLGaetano Lombardi
Gaetano Lombardi
RPRosario Pivonello
Rosario Pivonello
Objective: The objective of the study was to evaluate the efficacy of 5 yr of depot somatostatin analogs (SSAs) as first-line therapy in acromegaly. Outcome Measures: Primary measures were fasting GH 2.5 μg/liter or less and IGF-I normalized for age and tumor shrinkage. Secondary measures were control of hypertension, arrhythmias, left ventricular hypertrophy, diastolic and systolic dysfunction, and change in lipid and glucose profile. Patients: Patients included 45 de novo patients (18 women and 27 men, aged 20–82 yr); 28 were treated with octreotide-long-acting release and 17 with lanreotide. Results: GH was controlled in 100% and IGF-I levels in 97.8%, tumor shrinkage was 74.9 ± 22.1 and 78.2±14.5%, in the octreotide-long-acting release and lanreotide groups, respectively. There was a significant improvement in the prevalence of hypertension (from 46.7 to 22.2%, P = 0.027), arrhythmias (from 17.8% to zero, P = 0.01), left ventricular hypertrophy (from 82.2 to 42.2%, P < 0.0001), diastolic dysfunction (from 60.0 to 15.6%, P < 0.0001), systolic dysfunction (from 40.0 to 4.4%, P < 0.0001), and hypertriglyceridemia (from 40.0 to 4.4%, P < 0.0001). The prevalence of impaired glucose tolerance (IGT; from 28.9 to 20.0%. P = 0.46) and diabetes mellitus (from 22.4 to 31.1%, P = 0.64) did not change. Conclusions: In patients with severe comorbidities and those who refuse surgery, 5 yr of exclusive SSA therapy induce successful control of GH and IGF-I; tumor shrinkage (by median 80%), and improvement of hypertension, cardiac performance; and dyslipidemia. No patient was withdrawn from treatment because of side effects, and glucose tolerance was stable. We suggest that first-line SSA treatment may be safely continued in patients with acromegaly, according to an individual patient’s indications and preferences. A significant decrease in prevalence of hypertension, arrhythmias, left ventricular hypertrophy, diastolic and systolic dysfunction, and hypertriglyceridemia was found in 45 patients with acromegaly treated exclusively with depot somatostatin analogues for 5 years.

1 June 2006 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
Annamaria ColaoAnnamaria Colao
Annamaria Colao
RPRosario Pivonello
Rosario Pivonello
RARenata S. Auriemma
Renata S. Auriemma
FBFrancesco Briganti
Francesco Briganti
MGMariano Galdiero
Mariano Galdiero
GLGaetano Lombardi
Gaetano Lombardi
Context: Primary treatment with depot octreotide and lanreotide induces tumor shrinkage in newly diagnosed patients with acromegaly. Objective: The objective of the study was to evaluate clinical predictors of tumor shrinkage. Design: This was an analytical, observational, open, prospective study. Subjects: The study included 99 patients: 13 with microadenoma and 86 with macroadenoma (25 enclosed, 32 extrasellar, 29 invasive). Main Outcome Measures: Age, gender, estimated disease duration, body mass index, GH and IGF-I levels, and tumor volume at diagnosis and after 12 months of treatment were measured. Percentage of GH, IGF-I, and tumor size changes from baseline were also analyzed. Tumor changes were scored as absent (± 0–25%), mild (± 25.1–50%), moderate (± 50.1–75%), or notable (75%). Interventions: Sixty patients (60.6%) received depot octreotide im (20–30 mg every 28 d), and 39 patients (39.4%) received lanreotide im (60–90 mg every 28 d). Results: Basal tumor volume and maximal tumor diameter correlated with age, disease duration, and GH levels. After 12 months, GH levels were controlled (≤2.5 μg/liter) in 57.6%, IGF-I levels in 45.5%, and both in 42.4%. Shrinkage was absent in 22 patients (22.2%), mild in 31 (31.1%), moderate in 30 (30.3%), and notable in 14 patients (14.1%). Two patients (not responding to treatment) had a mild tumor increase (by 34 and 31.2%, respectively). Basal and posttreatment tumor volumes were highly correlated (r = 0.79, P < 0.0001). At the multistep regression analysis, the percent IGF-I decrease (t = 2.6; P = 0.011) was the best predictor of posttreatment tumor volume, followed by patients’ age (t = 2.1; P = 0.042) and percent GH decrease (t = 2.0; P = 0.044). Conclusions: Most patients with acromegaly (75.5%) had 25% or greater tumor shrinkage after 12 months of primary somatostatin analog therapy: significant increase of tumor mass occurred in only 2.1% of patients (uncontrolled during treatment). Best predictor of tumor shrinkage was posttreatment IGF-I.

1 November 2011 in European Journal of Endocrinology
Verified
Journal Article
Closed access
Annamaria ColaoAnnamaria Colao
Annamaria Colao
RPRosario Pivonello
Rosario Pivonello
LGLudovica Francesca Stella Grasso
Ludovica Francesca Stella Grasso
RARenata Simona Auriemma
Renata Simona Auriemma
MGMariano Galdiero
Mariano Galdiero
GLGaetano Lombardi
Gaetano Lombardi
Context: The most frequent cause of death in acromegaly is cardiomyopathy.Objective: To evaluate determinants of acromegalic cardiomyopathy.Design: Observational, open, controlled, retrospective study.Subjects: Two hundred and five patients with newly diagnosed active acromegaly (108 women and 97 men; median age 44 years) and 410 non-acromegalic subjects sex- and age-matched with the patients.Main outcome measures: Left ventricular (LV) mass index (LVMi), transmitral inflow early-to-atrial (E/A) peak velocity ratio, and LV ejection fraction (LVEF) were measured by Doppler echocardiography to determine the prevalence of LV hypertrophy (LVH), diastolic and systolic dysfunction. The role of age, estimated disease duration, body mass index, GH and IGF1 levels, systolic and diastolic blood pressure, lipid profile and glucose tolerance in determining different features of the acromegalic cardiomyopathy was investigated.Results: Compared with controls, the patients had lower E/A, LVEF, high-density lipoprotein (HDL)-cholesterol levels and higher LVMi, total- and low-density lipoprotein (LDL)-cholesterol, triglycerides, glucose and insulin levels, homeostatic model assessment of insulin resistance (HOMA-R) and HOMA-β. The relative risk to develop mild (odds ratio (OR)=1.67 (1.05–2.66);P=0.027) or severe hypertension (OR=1.58 (1.04–2.32);P=0.027), arrhythmias (OR=4.93 (1.74–15.9);P=0.001), impaired fasting glucose/impaired glucose tolerance (OR=2.65 (1.70–4.13);P<0.0001), diabetes (OR=2.14 (1.34–3.40);P=0.0009), LVH (OR=11.9 (7.4–19.5);P<0.0001), diastolic (OR=3.32 (2.09–5.31);P<0.0001) and systolic dysfunction (OR=14.2 (6.95–32.2);P10 years had a relative risk to present cardiac complications three times higher than patients with estimated disease duration ≤5 years.Conclusions: The prevalence of different features of cardiomyopathy is 3.3–14.2 times higher in the acromegalic than in the non-acromegalic population. The major determinant of cardiomyopathy is disease duration.

17 December 2013 in Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
RARenata S. Auriemma
Renata S. Auriemma
LGLuciana Granieri
Luciana Granieri
MGMariano Galdiero
Mariano Galdiero
CSChiara Simeoli
Chiara Simeoli
YPYlenia Perone
Ylenia Perone
RPRosario Pivonello
Rosario Pivonello
Introduction: Hyperprolactinemia has been implicated in the pathogenesis of obesity and glucose intolerance and is reportedly associated with an impaired metabolic profile. The current study aimed at investigating the effects of 12- and 60-month treatment with cabergoline (CAB) on metabolic syndrome (MetS) in patients with prolactinomas. Patients and Methods: 61 patients with prolactinomas (13 men, 48 women, 41 with microadenoma, 20 with macroadenoma), aged 34.4 ± 10.3 years, entered the study. In all patients, prolactin (PRL) and metabolic parameters were assessed at diagnosis and after 12 and 60 months of continuous CAB treatment. MetS was diagnosed according to NCEP-ATP III criteria. Results: Compared to baseline, CAB induced a significant decrease in PRL with complete normalization in 93% of patients after the 60-month treatment. At baseline, MetS prevalence was significantly higher in patients with PRL above (34.5%) than in those with PRL lower (12.5%) than the median (129 μg/l, p = 0.03). MetS prevalence significantly decreased after 12 (11.5%, p = 0.039) and 60 (5.0%, p = 0.001) months compared to baseline (28.0%). At both evaluations the lipid profile significantly improved compared to baseline. Fasting insulin and homeostatic model assessment of insulin resistance significantly decreased after 1 year of CAB (p = 0.012 and p = 0.002, respectively) and further improved after 60 months (p = 0.000). The visceral adiposity index significantly decreased after the 60-month treatment (p = 0.000) compared to baseline. At the 5-year evaluation CAB dose was the best predictor of percent decrease in fasting insulin (t = 2.35, p = 0.022). Conclusions: CAB significantly reduces MetS prevalence and improves the adipose tissue dysfunction index. The improvement in PRL, insulin sensitivity and other metabolic parameters might reflect the direct effect of CAB.

14 November 2006 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
RPRosario Pivonello
Rosario Pivonello
MGMaurizio Galderisi
Maurizio Galderisi
RARenata S. Auriemma
Renata S. Auriemma
MMMaria Cristina De Martino
Maria Cristina De Martino
MGMariano Galdiero
Mariano Galdiero
ACAnnamaria Colao
Annamaria Colao
Aim: The aim of the current study was to evaluate the effect of short-term (6 months) and long-term (18 months) treatment with pegvisomant on cardiac structure and performance in patients with acromegaly. Patients: Seventeen patients (nine women, eight men, 27–61 yr) with active acromegaly entered and 12 completed the long-term study. After a baseline evaluation, including measurement of hemodynamic, biochemical, and hormonal parameters, and a standard Doppler echocardiography, treatment with pegvisomant was started at the initial dose of 10 mg/d, increasing by 5 mg/d every 6 wk on the basis of IGF-I levels until normalization or the achievement of a maximal dose of 40 mg/d. Results: After short-term treatment, IGF-I levels were normalized in 10 of the 17 (59%) patients. Left ventricular mass index (LVMi) was significantly decreased without changes in diastolic and systolic performance. After long-term treatment, IGF-I levels were normalized in 10 of the 12 (83%) patients. Blood glucose and serum insulin levels were decreased compared with baseline. LVMi was further decreased compared with short-term treatment, so that the prevalence of left ventricle hypertrophy decreased from 50% at baseline to 17% after 18 months of treatment. Moreover, ejection fraction as well as early to late (atrial) peak velocity ratio (E/A) were significantly increased, whereas isovolumic relaxation time was significantly decreased compared with baseline, demonstrating an improvement of both diastolic and systolic function. A significant correlation was found between the change in IGF-I levels and that of left ventricular ejection fraction. In general, the prevalence of cardiac insufficiency was present in 13 of the 17 (76%) patients at baseline and in one (8%) patient after 18 months of treatment. Conclusions: Long-term treatment with the GH receptor antagonist improves acromegalic cardiomyopathy by decreasing cardiac hypertrophy and enhancing diastolic and systolic function, and consequently partially or completely reverting the cardiac insufficiency.

1 July 2008 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
Annamaria ColaoAnnamaria Colao
Annamaria Colao
RPRosario Pivonello
Rosario Pivonello
MGMaurizio Galderisi
Maurizio Galderisi
PCPaolo Cappabianca
Paolo Cappabianca
RARenata S. Auriemma
Renata S. Auriemma
GLGaetano Lombardi
Gaetano Lombardi
Objective: The objective of the study was to investigate whether first-line surgery or somatostatin analogs (SSA) have a different outcome on cardiomyopathy after 12 months. Design: This was a retrospective, comparative, nonrandomized study. Patients: Fifty-six patients treated with SSA and 33 operated on by transsphenoidal approach participated in the study. For the purposes of this study, only controlled patients were included. Measurements: Primary outcome measures were changes in left ventricular mass index, diastolic (early to atrial mitral flow velocity), and systolic performance (left ventricular ejection fraction). Secondary outcome measures were reduction of total to high-density lipoprotein-cholesterol ratio as a cardiovascular risk parameter, and improvement of glucose profile and pituitary function as indirect causes of cardiovascular improvement. Results: SSA and surgery groups were similar for gender, age, estimated disease duration, GH and IGF-I levels, and severity of cardiomyopathy lipid and glucose profile. Twelve months after treatment in both groups, left ventricular mass index, early to atrial mitral flow velocity, diastolic blood pressure, and heart rate decreased significantly, whereas only in SSA-treated patients, left ventricular ejection fraction increased significantly. The total to high-density lipoprotein-cholesterol ratio significantly reduced only in SSA-treated patients, whereas fasting glucose levels significantly decreased only in surgery-treated patients. A normal pituitary function was found in 46.4% of SSA- and 36.4% of surgery-treated patients, with results unchanged in the former and slightly reduced in the latter. Conclusions: Twelve months after first-line treatment with SSA or surgery, we found a similar improvement in left ventricular hypertrophy and diastolic filling. In contrast, systolic function improved more evidently in SSA-treated patients. Both a direct effect of SSA and a more preserved pituitary function might explain these results.